



## Clinician Virtual Review Meeting

---

December 14, 2021

10:00 am – 6:00 pm ET

### Participant Instructions

Follow the instructions below 15 minutes before the scheduled start time.

1. Please click on the Meeting link:  
<https://nqf.webex.com/nqf/j.php?MTID=m3a4347e55d4f4531fe24bbd521d25d86>
2. Meeting number: **179 144 0068** / Password: **Y5SyRffqC54**
3. To join by phone please call 415-655-0001 and enter the access code: **179 144 0068**
4. To unmute/mute your phone line use \*6.

### Meeting Objectives

- Review and provide input on Measures Under Consideration (MUC) of the MAP Clinician programs
- Identify measure gaps for the MAP Clinician programs

- |                 |  |
|-----------------|--|
| <b>10:00 am</b> | <b>Welcome and Review of Meeting Objectives</b><br><i>Dana Gelb Safran, CEO and President, NQF</i><br><i>Rob Fields, MAP Clinician Workgroup Co-Chair</i><br><i>Diane Padden, MAP Clinician Workgroup Co-Chair</i><br><i>Tricia Elliott, Senior Managing Director, NQF</i> |
| <b>10:30 am</b> | <b>CMS Opening Remarks</b><br><i>Michelle Schreiber, Deputy Director for Quality and Value, CMS</i>  |
| <b>11:00 am</b> | <b>Discussion on Shared Savings Program</b><br><i>CMS Representative</i>   |
| <b>11:15 am</b> | <b>Overview of Pre-Rulemaking Approach</b><br><i>Ivory Harding, Manager, NQF</i> <ul style="list-style-type: none"><li>• Review preliminary analysis algorithm</li><li>• Review decision categories</li><li>• Review voting procedures</li></ul>                           |
| <b>12:00 pm</b> | <b>MAP Rural Health Advisory Group and MAP Health Equity Advisory Group</b><br><i>Chelsea Lynch, Director, NQF</i> <ul style="list-style-type: none"><li>• Review of Advisory Group Charges</li></ul>  |
| <b>12:30 pm</b> | <b>Lunch</b>   |
| <b>1:00 pm</b>  | <b>Medicare Part C and D Star Ratings</b> <ul style="list-style-type: none"><li>• Provide program overview</li></ul>   |

- Opportunity for public comment
- Pre-rulemaking input
  - *MUC2021-053: Concurrent Use of Opioids and Benzodiazepines (COB)*
  - *MUC2021-056: Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults (Poly-ACH)*
  - *MUC2021-066: Polypharmacy: Use of Multiple Central Nervous System (CNS)-Active Medications in Older Adults (Poly-CNS)*

**2:30 pm**      **Break**

**2:40 pm**      **Merit-Based Incentive Payment System (MIPS) Measures**

- Provide program overview
- Opportunity for public comment
- Pre-rulemaking input
  - *MUC2021-125: Psoriasis – Improvement in Patient-Reported Itch Severity*
  - *MUC2021-135: Dermatitis – Improvement in Patient-Reported Itch Severity*
  - *MUC2021-063: Care Goal Achievement Following a Total Hip Arthroplasty (THA) or Total Knee Arthroplasty (TKA)*
  - *MUC2021-107: Clinician-Level and Clinician Group-Level Total Hip Arthroplasty and/or Total Knee Arthroplasty (THA and TKA) Patient-Reported Outcome-Based Performance Measure (PRO-PM)*
  - *MUC2021-090: Kidney Health Evaluation*
  - *MUC2021-127: Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy*
  - *MUC2021-105: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma*
  - *MUC2021-058: Appropriate intervention of immune-related diarrhea and/or colitis in patients treated with immune checkpoint inhibitors*

**4:40 pm**      **Cross Cutting Measures**

- Provide program overview
- Opportunity for public comment
- Pre-rulemaking input
  - *MUC2021-134: Screen Positive Rate for Social Drivers of Health*
  - *MUC2021-136: Screening for Social Drivers of Health*

**5:30 pm**      **Opportunity for Public Comment**

**5:45 pm**      **Summary of Day and Next Steps**

*Rob Fields*  
*Diane Padden*  
*Tricia Elliott*

**6:00 pm**      **Adjourn**